BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's MacroglobulinemiaBusiness Wire • 03/15/22
Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?InvestorPlace • 03/11/22
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid TumorsBusiness Wire • 03/11/22
MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listingsMarket Watch • 03/10/22
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone LymphomaBusiness Wire • 03/03/22
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone LymphomaBusiness Wire • 02/22/22
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic LeukemiaBusiness Wire • 02/22/22
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström's MacroglobulinemiaBusiness Wire • 02/17/22
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology ConferenceBusiness Wire • 02/08/22
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of DirectorsBusiness Wire • 02/01/22
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy DesignationBusiness Wire • 01/28/22
BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction CancerBusiness Wire • 01/24/22
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström's MacroglobulinemiaBusiness Wire • 01/20/22
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerBusiness Wire • 01/06/22
Novartis Inks Option Agreement For BeiGene Anti-Cancer Therapy For Over $1 BillionBenzinga • 12/20/21